A novel dual-action drug TJ94 facilitated by lipid nanocrystal formulations targeting neuroprotection and antithrombosis in ischemic stroke
Source abstract
Abstract
Platelet aggregation and neuronal injury are central factors underlying the pathogenesis of ischemic stroke (IS), thus dual-acting drugs possessing both antiplatelet and neuroprotective effects are highly needed. We synthesized a novel dual-action drug-TJ94 for neuroprotective and anti-platelet action in IS. To facilitate intravenous administration of TJ94, we developed a lipid nanocrystal formulation (TJ94@LNC) to increase the solubility, brain accumulation and therapeutic of TJ94 effects on IS. Our results clearly indicated that TJ94@LNC has great potential in brain accumulation due to the enrichment of transferrin (Tf) and apolipoprotein A1 (ApoA1) in the protein corona, which might improve the therapeutic effects of TJ94 on middle cerebral artery occlusion/reperfusion (MCAO/R) rats in both the acute and chronic phase of IS. Consistent with the design of TJ94, its therapeutic effects are attributed to its neuroprotective properties, which include inhibiting oxidative stress and apoptosis, as well as its antiplatelet activity. This lipid nanocrystal nanoplatform effectively addresses the brain delivery challenges of TJ94 to synergistically exert dual-functional therapeutic effects. It provides an effective solution for the intravenous injection of lipid-soluble drugs for the treatment of IS. This research presents TJ94@LNC as a promising therapeutic nanoplatform for IS. Lipid nanocrystal nanoplatform effectively addresses the brain delivery challenges of TJ94 to synergistically exert dual-functional therapeutic effects, which improved the neuroprotective and anti-platelet effects of TJ94 on middle cerebral artery occlusion/reperfusion (MCAO/R) rats in both the acute and chronic phase of ischemic stroke.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Neuroinflammation and Neurodegeneration Mechanisms · Acute Ischemic Stroke Management · Antiplatelet Therapy and Cardiovascular Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Endothelial S1P(1) signaling counteracts infarct expansion in ischemic stroke10.1161/CIRCRESAHA.120.316711 ↗
2. Acute ischemic stroke therapy overview10.1161/CIRCRESAHA.116.309278 ↗
3. Multiple molecular penumbras after focal cerebral ischemia10.1097/00004647-200007000-00001 ↗
4. Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke10.1126/scitranslmed.abk0135 ↗
5. Erratum: edaravone-Encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability: erratum10.7150/thno.108498 ↗
6. Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system10.1186/s12951-024-02772-2 ↗
7. In vivo inhibition of miR-155 significantly alters post-stroke inflammatory response10.1186/s12974-016-0753-x ↗
8. Fibrinogen time course in acute ischemic stroke patients treated with intravenous thrombolysis with alteplase or tenecteplase10.1177/23969873251345387 ↗
9. Matrilin-3 supports neuroprotection in ischemic stroke by suppressing astrocyte-mediated neuroinflammation10.1016/j.celrep.2024.113980 ↗
10. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial10.1001/jama.2020.23522 ↗
11. Antiplatelet effect of ginkgo diterpene lactone meglumine injection in acute ischemic stroke: a randomized, double-blind, placebo-controlled clinical trial10.1002/ptr.7720 ↗
12. Synthesis of novel 3-Butylphthalide derivatives containing isopentenylphenol moiety as potential antiplatelet agents for the treatment of ischemic stroke10.1002/cbdv.202201002 ↗
13. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial10.1001/jamaneurol.2023.5716 ↗
14. Computational systems pharmacology reveals an antiplatelet and neuroprotective mechanism of deng-zhan-xi-xin injection in the treatment of ischemic stroke10.1016/j.phrs.2019.104365 ↗
15. A dual-target and dual-mechanism design strategy by combining inhibition and degradation together10.1021/jacs.4c11930 ↗
16. Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization10.1038/s41467-025-62645-6 ↗
17. Recent advances on nitrones design for stroke treatment10.1021/acs.jmedchem.0c00976 ↗
18. Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke10.1016/j.bmc.2008.08.075 ↗
19. Novel multi-functional nitrones for treatment of ischemic stroke10.1016/j.bmc.2012.04.016 ↗
20. The in vivo fate of nanocrystals10.1016/j.drudis.2017.01.003 ↗
21. Biological and intracellular fates of drug nanocrystals through different delivery routes: recent development enabled by bioimaging and PK modeling10.1016/j.addr.2022.114466 ↗
22. Unraveling the impact of stabilizers on nanocrystal preparation and oral absorption: a case study of poorly soluble andrographolide10.1021/acs.nanolett.4c05230 ↗
23. Recent developments in the use of nanocrystals to improve bioavailability of APIs10.1002/wnan.1958 ↗
24. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery10.1016/j.jconrel.2014.03.030 ↗
25. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs10.1007/s11095-012-0889-z ↗
26. Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems10.1007/s13346-024-01559-0 ↗
27. Recent advances in chemically engineered nanostructures impact on ischemic stroke treatment10.1021/acsomega.3c06228 ↗
28. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - an update10.1016/j.ijpharm.2017.10.051 ↗
29. A deep insight into stabilization strategies and surface modification of nanocrystals and their implications in drug delivery: focus on taxanes10.1016/j.ijpharm.2025.125794 ↗
30. Lipid-mediated protein Corona regulation with increased apolipoprotein A-I recruitment for glioma targeting10.1016/j.jconrel.2024.02.020 ↗
31. Influence of particle size on the aggregation behavior of nanoparticles: role of structural hydration layer10.1016/j.jes.2020.10.007 ↗
32. Exploring the coating of gold nanoparticles with lipids10.3390/nano15191516 ↗
33. Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke: the ATAMIS randomized clinical trial10.1001/jamaneurol.2024.0146 ↗
34. Molecularly self-fueled nano-penetrator for nonpharmaceutical treatment of thrombosis and ischemic stroke10.1038/s41467-023-35895-5 ↗
35. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets10.1016/S0049-3848(97)00253-3 ↗
36. Antiplatelet activity of tetramethylpyrazine via regulation of the P2Y12 receptor downstream signaling pathway10.1155/2022/7941039 ↗
37. Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers10.1016/j.intimp.2019.105967 ↗
38. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo10.1124/jpet.108.148676 ↗
39. Structure of the human P2Y12 receptor in complex with an antithrombotic drug10.1038/nature13083 ↗
40. Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds10.1016/j.pharmthera.2021.107824 ↗
41. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix10.1080/10717544.2016.1245371 ↗
42. Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions10.1038/s41467-025-58746-x ↗
43. Artificial apolipoprotein corona enables nanoparticle brain targeting10.1016/j.nano.2017.11.008 ↗
44. Versatile hollow COF nanospheres via manipulating transferrin corona for precise glioma-targeted drug delivery10.1016/j.biomaterials.2020.120305 ↗
45. A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease10.1016/j.colsurfb.2015.06.025 ↗
46. Targeting transferrin receptor 1 for enhancing drug delivery through the blood-brain barrier for Alzheimer's disease10.3390/ijms26199793 ↗
47. Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model10.1016/j.ijpharm.2016.01.014 ↗